LUMA

A Phase 2b, multicenter, randomised, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122/DNL151 in subjects with Parkinson’s disease

Topic / Pathology

  • Parkinson's Disease

Objectives

To have more informations, click on the link below:

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 - Full Text View - ClinicalTrials.gov

Sponsor

Biogen

Status

Recruiting

Participating centers

Share

Updated on 05 August 2025